Engineered extracellular vesicles with polypeptide for targeted delivery of doxorubicin against EGFR‑positive tumors.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9422756 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-2431 (Electronic) Linking ISSN: 1021335X NLM ISO Abbreviation: Oncol Rep Subsets: MEDLINE
    • Publication Information:
      Publication: <2003->: Athens : D.A. Spandidos
      Original Publication: [Athens, Greece] : National Hellenic Research Foundation, 1994-
    • Subject Terms:
      Doxorubicin*/pharmacology ; Doxorubicin*/administration & dosage ; ErbB Receptors*/metabolism ; Extracellular Vesicles*/metabolism ; Drug Delivery Systems* ; Cell Proliferation*/drug effects ; Peptides*/administration & dosage; Humans ; Cell Line, Tumor ; Apoptosis/drug effects ; Cell Survival/drug effects ; Neoplasms/drug therapy ; Neoplasms/pathology
    • Abstract:
      Lack of effective tumor‑specific delivery systems remains an unmet clinical challenge for the employment of chemotherapy using cytotoxic drugs. Extracellular vesicles (EVs) have recently been investigated for their potential as an efficient drug‑delivery platform, due to their good biodistribution, biocompatibility and low immunogenicity. In the present study, the formulation of GE11 peptide‑modified EVs (GE11‑EVs) loaded with doxorubicin (Dox‑GE11‑EVs), was developed to target epidermal growth factor receptor (EGFR)‑positive tumor cells. The results obtained demonstrated that GE11‑EVs exhibited highly efficient targeting and drug delivery to EGFR‑positive tumor cells compared with non‑modified EVs. Furthermore, treatment with Dox‑GE11‑EVs led to a significantly inhibition of cell proliferation and increased apoptosis of EGFR‑positive tumor cells compared with Dox‑EVs and free Dox treatments. In addition, it was observed that treatment with either free Dox or Dox‑EVs exhibited a high level of cytotoxicity to normal cells, whereas treatment with Dox‑GE11‑EVs had only a limited effect on cell viability of normal cells. Taken together, the findings of the present study demonstrated that the engineered Dox‑GE11‑EVs can treat EGFR‑positive tumors more accurately and have higher safety than traditional tumor therapies.
    • References:
      J Adv Res. 2018 Jun 25;15:1-18. (PMID: 30581608)
      J Cell Biol. 2015 Jan 5;208(1):7. (PMID: 25559181)
      Biochem Biophys Res Commun. 2016 Mar 25;472(1):53-9. (PMID: 26902116)
      Acta Biomater. 2019 Aug;94:482-494. (PMID: 31129363)
      J Control Release. 2023 Jan;353:1127-1149. (PMID: 36528193)
      Biomaterials. 2021 Jun;273:120784. (PMID: 33848731)
      J Control Release. 2021 Aug 10;336:510-521. (PMID: 34237399)
      Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232. (PMID: 7612182)
      Andrologia. 2021 Mar;53(2):e13738. (PMID: 32706440)
      Pharmacol Ther. 1999 May-Jun;82(2-3):241-50. (PMID: 10454201)
      J Pathol. 2003 Feb;199(2):221-8. (PMID: 12533835)
      Mol Ther. 2013 Jan;21(1):185-91. (PMID: 23032975)
      Biotechnol Adv. 2022 Oct;59:107983. (PMID: 35588952)
      Crit Rev Oncol Hematol. 2007 Aug;63(2):160-71. (PMID: 17544289)
      FASEB J. 2005 Dec;19(14):1978-85. (PMID: 16319141)
      Cell Res. 2018 Aug;28(8):833-854. (PMID: 30030520)
      Biomaterials. 2017 Oct;142:1-12. (PMID: 28715655)
      Science. 2008 Feb 29;319(5867):1244-7. (PMID: 18309083)
      J Ethnopharmacol. 2024 Jul 15;329:118001. (PMID: 38467318)
      Angew Chem Int Ed Engl. 2006 Dec 11;45(48):8149-52. (PMID: 17099918)
      Nat Biotechnol. 2011 Apr;29(4):325-6. (PMID: 21478846)
      Theranostics. 2019 Feb 28;9(6):1714-1727. (PMID: 31037133)
      J Cell Mol Med. 2023 Sep;27(18):2661-2674. (PMID: 37431884)
      Biomed Pharmacother. 2020 Jan;121:109139. (PMID: 31707337)
      Mol Pharm. 2018 Sep 4;15(9):3664-3671. (PMID: 29570299)
      Bioeng Transl Med. 2020 Dec 03;6(3):e10203. (PMID: 34589592)
      Artif Cells Nanomed Biotechnol. 2023 Dec;51(1):532-546. (PMID: 37948136)
      J Cell Physiol. 2022 Jan;237(1):911-933. (PMID: 34463962)
      Curr Med Chem. 2019;26(33):6132-6148. (PMID: 30182846)
      J Card Fail. 2000 Mar;6(1):43-6. (PMID: 10746818)
      Neuro Oncol. 2022 Dec 1;24(12):2035-2062. (PMID: 36125064)
      Cancer Sci. 2019 Oct;110(10):3173-3182. (PMID: 31464035)
      J Nanobiotechnology. 2020 Jan 9;18(1):10. (PMID: 31918721)
      BMC Cancer. 2021 Jul 8;21(1):791. (PMID: 34238253)
      Front Immunol. 2020 Nov 27;11:578877. (PMID: 33329549)
      Acta Biomater. 2017 Dec;64:323-333. (PMID: 29030307)
      J Mater Chem B. 2022 Nov 16;10(44):9266-9279. (PMID: 36342458)
    • Contributed Indexing:
      Keywords: EGFR‑positive cancer; chemotherapy; colorectal cancer; engineered extracellular vesicles; glioma; targeted drug delivery
    • Accession Number:
      80168379AG (Doxorubicin)
      EC 2.7.10.1 (ErbB Receptors)
      EC 2.7.10.1 (EGFR protein, human)
      0 (GE11 peptide)
      0 (Peptides)
    • Publication Date:
      Date Created: 20240927 Date Completed: 20240927 Latest Revision: 20241012
    • Publication Date:
      20241012
    • Accession Number:
      PMC11465103
    • Accession Number:
      10.3892/or.2024.8813
    • Accession Number:
      39329273